Centessa Pharmaceuticals plc — Director's Dealing 2021

Jun 4, 2021

SEC Form 3/A — Form 3/A

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-05-27

Reporting Person: Weinhoff Gregory M (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Share Option (right to buy)	$5.84	2031-03-04	Ordinary Shares (639321)		Direct
Share Option (right to buy)	$5.84	2031-03-04	Ordinary Shares (319660)		Indirect

Footnotes

F1: 25% of the shares subject to such option shall vest and become exercisable on March 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

F2: Represents A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.

F3: Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F4: Held by Gregory Weinhoff 2017 Trust, a spousal lifetime access trust ("SLAT"), of which the Reporting Person's spouse and another immediate family member are trustees. The beneficiaries of the SLAT are the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of the securities held by the SLAT.